Taxol encapsulation in poly(? - caprolactone) microspheres

Dordunoo, Stephen K.; Jackson, John K.; Arsenault, Larry; Oktaba, Ann Marie C.; Hunter, William L.; Burt, Helen

doi:10.1007/s002800050323

Cited by 14 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, paclitaxel at a dose of 2 nM shortens sprouts to a striking degree and reduces cell migration in the ex vivo rat aortic ring assay (33). The antiangiogenic effect in vivo of paclitaxel as shown here and previously (9, 13, 34–38) and the fact that paclitaxel exerts a selective antiproliferative effect in human endothelial cells in vitro (32, 33, 39) makes it imperative to investigate its antiangiogenic effects, alone and in combination treatment schedules, in various preclinical models.…”

Section: Discussionmentioning

confidence: 76%

Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non‐tumor tissue in the same animals: a quantitative study

Lennernäs

Albertsson²,

Damber³

et al. 2004

APMIS

View full text Add to dashboard Cite

Well-tolerated continuous or metronomic chemotherapy can exert a marked antiangiogenic and thus superior antitumor effect compared with conventional high-dose, temporarily spaced-out chemotherapy, as shown in preclinical studies. There is, however, no means of directly assessing the antiangiogenic effect in a tumor, a serious impediment to assessing the effects of putative antiangiogenic chemotherapeutics or treatments. In an attempt to circumvent or minimize this impediment we studied the antiangiogenic effect of well-tolerated metronomic paclitaxel therapy in a surrogate tumor-free tissue that allows true quantitative analysis as well as in syngeneic At-1 prostate cancer in the same rat. This novel model allows an accurate comparison of the angiogenesis-modulating effect of chemotherapy in the two tissues to be made. The effect of chemotherapy on VEGF-A-mediated angiogenesis, a characteristic of most tumors, was assessed truly quantitatively by microscopic morphometry and image analysis in the tumor-free mesentery. The chemotherapy significantly suppressed VEGF-A-mediated angiogenesis in the mesentery to an extent that closely mirrored the significant increase in tumor necrosis measured morphometrically and the significant decrease in tumor growth rate. This finding opens an avenue to study quantitatively and systematically the antiangiogenic effect of chemotherapeutic modalities and treatments that approximately mirror their antiangiogenic effect in the At-1 tumor.

show abstract

Section: Discussionmentioning

confidence: 76%

Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non‐tumor tissue in the same animals: a quantitative study

Lennernäs

Albertsson²,

Damber³

et al. 2004

APMIS

View full text Add to dashboard Cite

show abstract

“…Unfortunately, this formulation has been observed to induce many adverse effects such as hypersensitivity and neurotoxicity [55]. Due to the problems of poor solubility and adverse effects associated with the available PTX formulation, scientists are trying to formulate it in many alternative and effective drug delivery systems, such as cyclodextrin [56,57], dendrimers [58], nanoparticles [59], prodrugs [60,61], liposomes [62], 2-methacryloyloxyethl phosphorylcholine polymers [63], and microspheres [64,65]. Moreover, a study performed by Mita et al involved a new drug delivery system devoid of cremophore and composed of porous PTX microspheres [66].…”

Section: Chitosan Microspheres For the Drug Delivery Of Ptxmentioning

confidence: 99%

Chitosan Microspheres for the Delivery of Chemotherapeutic Agents: Paclitaxel as a Model

Al-Najjar¹,

Hussain²

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Chitosan has unique physicochemical and biological features that suggest it as a good candidate for the development of safe and effective drug delivery systems. Linking drug molecules with chitosan through a functional spacer enables formulation of prodrugs that have appropriate pharmacological activities at specific desired sites. The development of formulations of targeted delivery systems for the chemotherapeutic agents, especially those with unfavorable pharmacokinetic features, like paclitaxel (PTX), can potentially alleviate the systemic cytotoxicity as well as directing therapy to the specific lesions. The main aim of this literature review is to critically evaluate the use of chitosan microspheres as a drug delivery system to enhance PTX distribution and efficacy in specific targeted sites.

show abstract

“…5 Dordunoo and colleagues reported the first published evidence about a possible antiangiogenic activity of paclitaxel more than 15 years ago. 6 Their study showed that Taxol inhibits angiogenesis in the chick chorioallantoic membrane (CAM) model. 6 Since then, a number of studies have reported on the antiangiogenic effects of Taxol in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

“…6 Their study showed that Taxol inhibits angiogenesis in the chick chorioallantoic membrane (CAM) model. 6 Since then, a number of studies have reported on the antiangiogenic effects of Taxol in vitro and in vivo. 7,8 Recent studies further showed that Taxol inhibits the growth and migration of endothelial cells.…”

Section: Introductionmentioning

confidence: 99%

Altered expression of platelet factor 4 and basic fibroblast growth factor correlates with the inhibition of tumor growth in mice

Mabeta

Pepper

2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Herein we describe the effects of Taxol on endothelioma cell growth and migration in vitro and on vascular tumor growth in vivo. The effects of Taxol on endothelioma cell growth were determined using the crystal violet assay, while cell migration was measured using the xCELLIgence Real Time Cell Analysis system. To study the effects of Taxol on tumor growth, mice were inoculated with endothelioma cells to induce vascular tumor development and were treated with the drug. At termination, tissue samples from Taxol-treated and control mice were stained with hematoxylin and eosin for histological examination, while blood samples were collected for hematological analysis, as well as for the analysis of the expression of angiogenic markers. In vitro, Taxol inhibited cell growth and migration. The drug also inhibited vascular tumor growth in mice, and this correlated with a recovery of mice from thrombocytopenia. Array analysis of blood samples from mice revealed that there was an increase in the expression of Platelet Factor 4 and a suppression of the proangiogenic molecule basic fibroblast growth factor in Taxol-treated animals. Our findings suggest that Taxol may have potential in the treatment of vascular tumors.

show abstract

Taxol encapsulation in poly(? - caprolactone) microspheres

Cited by 14 publications

References 0 publications

Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non‐tumor tissue in the same animals: a quantitative study

Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non‐tumor tissue in the same animals: a quantitative study

Chitosan Microspheres for the Delivery of Chemotherapeutic Agents: Paclitaxel as a Model

Altered expression of platelet factor 4 and basic fibroblast growth factor correlates with the inhibition of tumor growth in mice

Contact Info

Product

Resources

About